文献速递耳科与耳神经

顺铂化疗后耳毒性:患者报告结局与听力检查结果不一致的相关因素

Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments.
PubMed 文献 · Ear Hear · 2022-01-01

研究纳入1410例顺铂化疗后≥6个月的睾丸癌幸存者,行0.25至12 kHz听力检查和问卷,分析患者报告听力损失与听力检查定义听力损失不一致的因素,并评估听力检查定义听力损失的危险因素。

要点

  • 34.8%的睾丸癌幸存者自报听力损失。
  • 无耳鸣者中,仅扩展高频或扩展高频加标准频率听力损失者更易自报听力损失。
  • 高龄、混合性/传导性听力损失、未用助听器、低教育程度与低估听力损失严重程度相关。

核心结论

  • 顺铂化疗后患者报告与听力检查定义的听力损失不一致由多种因素导致。
  • 对自报听力损失但标准频率听力检查正常者,可考虑转诊听力学家进一步测试并将扩展高频纳入听力评估。

研究设计与样本

  • 研究纳入1410例顺铂化疗后≥6个月的睾丸癌幸存者,进行0.25至12 kHz综合听力评估并完成问卷。
  • 听力损失严重程度采用美国言语语言听力协会标准定义。
  • 采用多变量多项回归分析患者报告与听力检查定义听力损失不一致的相关因素,采用多变量有序回归评估听力检查定义听力损失的相关因素。

主要发现

  • 34.8%的睾丸癌幸存者自报听力损失。
  • 无耳鸣者中,仅扩展高频(10至12 kHz)听力损失者(17.8%)和扩展高频加标准频率(0.25至8 kHz)听力损失者(23.4%)自报听力损失的可能性显著高于无听力检查定义听力损失者(8.1%),OR分别为2.48(95%CI 1.31至4.68)和3.49(95%CI 1.89至6.44)。
  • 较老年龄(OR=1.09,95%CI 1.07至1.11,p<0.0001)、无既往噪声暴露(OR=1.40,95%CI 1.06至1.84,p=0.02)、混合性/传导性听力损失(OR=2.01,95%CI 1.34至3.02,p=0.0007)、未使用助听器(OR=5.64,95%CI 1.84至17.32,p=0.003)和较低教育程度(高中或以下 vs 研究生教育,OR=2.12,95%CI 1.23至3.67,p=0.007)与更大程度低估听力检查定义听力损失严重程度相关。
  • 耳鸣与更大程度高估听力损失严重程度相关(轻度耳鸣OR=4.65,95%CI 2.64至8.20;中度耳鸣OR=5.87,95%CI 2.65至13.04;重度耳鸣OR=10.57,95%CI 4.91至22.79,p<0.0001)。
  • 较老年龄(OR=1.13,95%CI 1.12至1.15,p<0.0001)、累积顺铂剂量>300 mg/m2(OR=1.47,95%CI 1.21至1.80,p=0.0001)和高血压(OR=1.80,95%CI 1.28至2.52,p=0.0007)与更严重的美国言语语言听力协会定义听力损失相关,研究生教育(OR=0.58,95%CI 0.40至0.85,p=0.005)与较轻听力损失相关。

临床怎么用

  • 对自报听力损失但标准频率听力检查正常的幸存者,可考虑转诊听力学家进行额外测试并将扩展高频纳入听力评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To provide new information on factors associated with discrepancies between patient-reported and audiometrically defined hearing loss (HL) in adult-onset cancer survivors after cisplatin-based chemotherapy (CBCT) and to comprehensively investigate risk factors associated with audiometrically defined HL. DESIGN: A total of 1410 testicular cancer survivors (TCS) ≥6 months post-CBCT underwent comprehensive audiometric assessments (0.25 to 12 kHz) and completed questionnaires. HL severity was defined using American Speech-Language-Hearing Association criteria. Multivariable multinomial regression identified factors associated with discrepancies between patient-reported and audiometrically defined HL and multivariable ordinal regression evaluated factors associated with the latter. RESULTS: Overall, 34.8% of TCS self-reported HL. Among TCS without tinnitus, those with audiometrically defined HL at only extended high frequencies (EHFs) (10 to 12 kHz) (17.8%) or at both EHFs and standard frequencies (0.25 to 8 kHz) (23.4%) were significantly more likely to self-report HL than those with no audiometrically defined HL (8.1%) [odds ratio (OR) = 2.48; 95% confidence interval (CI), 1.31 to 4.68; and OR = 3.49; 95% CI, 1.89 to 6.44, respectively]. Older age (OR = 1.09; 95% CI, 1.07 to 1.11, p < 0.0001), absence of prior noise exposure (OR = 1.40; 95% CI, 1.06 to 1.84, p = 0.02), mixed/conductive HL (OR = 2.01; 95% CI, 1.34 to 3.02, p = 0.0007), no hearing aid use (OR = 5.64; 95% CI, 1.84 to 17.32, p = 0.003), and lower education (OR = 2.12; 95% CI, 1.23 to 3.67, p = 0.007 for high school or less education versus postgraduate education) were associated with greater underestimation of audiometrically defined HL severity, while tinnitus was associated with greater overestimation (OR = 4.65; 95% CI, 2.64 to 8.20 for a little tinnitus, OR = 5.87; 95% CI, 2.65 to 13.04 for quite a bit tinnitus, and OR = 10.57; 95% CI, 4.91 to 22.79 for very much tinnitus p < 0.0001). Older age (OR = 1.13; 95% CI, 1.12 to 1.15, p < 0.0001), cumulative cisplatin dose (>300 mg/m2, OR = 1.47; 95% CI, 1.21 to 1.80, p = 0.0001), and hypertension (OR = 1.80; 95% CI, 1.28 to 2.52, p = 0.0007) were associated with greater American Speech-Language-Hearing Association-defined HL severity, whereas postgraduate education (OR = 0.58; 95% CI, 0.40 to 0.85, p = 0.005) was associated with less severe HL. CONCLUSIONS: Discrepancies between patient-reported and audiometrically defined HL after CBCT are due to several factors. For survivors who self-report HL but have normal audiometric findings at standard frequencies, referral to an audiologist for additional testing and inclusion of EHFs in audiometric assessments should be considered.

来源:Ear Hear,查看原文。版权归原作者所有。

引用

  1. Ardeshirrouhanifard S, Fossa SD, Huddart R, et al. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments. Ear Hear. 2022. PMID: 35067571. doi:10.1097/AUD.0000000000001172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。